Immunic (IMUX) Income from Continuing Operations (2013 - 2026)
Immunic (IMUX) posted Income from Continuing Operations of 35805853.0 for Q1 2026, up 74.96% sequentially from 143003000.0 in Q4 2025, and down 34.31% YoY from 54509304.76 in Q1 2025.
Powered by 
Analysis
Immunic (IMUX) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Immunic has reported Income from Continuing Operations for 14 years, with the latest figure at 35805853.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 34.31% year-over-year to 35805853.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 232365815.0 (down 129.02% YoY) and the FY2025 annual result came in at 222061000.0, down 4.87% from the prior year.
- Income from Continuing Operations climbed to 35805853.0 in Q1 2026 per IMUX's latest filing, from 143003000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 19888400.0 in Q3 2022 and troughed at 143003000.0 in Q4 2025.
- A 5-year average of 43977912.35 and a median of 26612428.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations slumped 497.2% in 2022, then jumped 79.29% in 2024.
- Over 5 years, Income from Continuing Operations stood at 129682000.0 in 2022, then advanced by 6.01% to 121891000.0 in 2023, then surged by 79.29% to 25240000.0 in 2024, then slumped by 466.57% to 143003000.0 in 2025, then soared by 74.96% to 35805853.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 35805853.0, 143003000.0, and 26632962.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Immunic | 544.60 Mn | 544.60 Mn | - | -34.04 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -34.04 Mn |
| Mar 31, 2026 | -32.48 Mn |
| Dec 31, 2025 | -23.13 Mn |
| Sep 30, 2025 | -25.57 Mn |
| Jun 30, 2025 | -26.84 Mn |
| Mar 31, 2025 | -26.64 Mn |
| Dec 31, 2024 | -25.20 Mn |
| Sep 30, 2024 | -24.95 Mn |
| Jun 30, 2024 | -21.82 Mn |
| Mar 31, 2024 | -22.69 Mn |
| Dec 31, 2023 | -22.84 Mn |
| Sep 30, 2023 | -22.80 Mn |
| Jun 30, 2023 | -24.05 Mn |
| Mar 31, 2023 | -26.45 Mn |
| Dec 31, 2022 | -56.63 Mn |
| Sep 30, 2022 | -19.89 Mn |
| Jun 30, 2022 | -20.50 Mn |
| Mar 31, 2022 | -21.43 Mn |
| Dec 31, 2021 | -21.71 Mn |
| Sep 30, 2021 | -18.38 Mn |